US to review trials to stop genetic data misuse by China, ‘hostile’ nations
HQ Team June 19, 2025: The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team June 19, 2025: The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’.
HQ Team July 13, 2025: Denmark’s Novo Nordisk A/S will advance its experimental drug amycretin, in both injection and oral forms, into end-stage.
HQ Team June 10, 2025: Merck & Co.’s two oral cholesterol pill trials — one mid-stage and the other end-stage — showed “positive.
HQ Team June 10, 2025: The Food and Drug Administration has approved Merck & Co. Inc.’s jab for preventing respiratory syncytial virus (RSV).
HQ Team June 4, 2025: A third of patients with a type of blood cancer, especially those whose disease had returned or not.
HQ Team June 2, 2025: US-based Bristol Myers Squibb announced a $11.1 billion pact with Germany’s BioNTech SE for global co-development and co-commercialisation.
HQ Team June 1, 2025: Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.’s antibody-drug conjugate, cut the risk of an.
HQ Team May 29, 2025: The US Department of Health and Human Services has terminated a contract awarded to Moderna Inc. for the.
HQ Team May 28, 2025: GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract.
HQ Team May 28, 2025: Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor.